{"id":"m-001","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"M-001 (Multimeric-001) is a universal influenza vaccine candidate that uses a recombinant protein platform to present conserved epitopes from multiple influenza virus strains. By targeting conserved regions across different flu strains, it aims to generate cross-protective immunity that extends beyond the specific strains included in seasonal vaccines, potentially providing broader and more durable protection.","oneSentence":"M-001 is a multivalent recombinant influenza vaccine designed to stimulate broad immune responses against multiple influenza strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:19:57.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Influenza prevention (universal/broad-spectrum protection)"}]},"trialDetails":[{"nctId":"NCT06528080","phase":"EARLY_PHASE1","title":"A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-01","conditions":"Gaucher Disease","enrollment":9},{"nctId":"NCT06818838","phase":"PHASE1, PHASE2","title":"A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease","status":"RECRUITING","sponsor":"Lingyi Biotech Co., Ltd.","startDate":"2024-07-05","conditions":"Gaucher Disease Type 1","enrollment":12},{"nctId":"NCT07096882","phase":"PHASE1","title":"SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection","status":"RECRUITING","sponsor":"Cytocraft Biopharmaceutical Co., Ltd.","startDate":"2025-07-26","conditions":"Non-Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT06162338","phase":"NA","title":"A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I","status":"RECRUITING","sponsor":"He Huang","startDate":"2023-11-15","conditions":"Gaucher Disease Type I","enrollment":3},{"nctId":"NCT03450915","phase":"PHASE3","title":"A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2018-08-01","conditions":"Influenza","enrollment":12460},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT02691130","phase":"PHASE2","title":"Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2015-11","conditions":"Influenza, Healthy","enrollment":224},{"nctId":"NCT02293317","phase":"PHASE2","title":"Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2014-11","conditions":"Influenza","enrollment":37},{"nctId":"NCT01419925","phase":"PHASE2","title":"A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2011-08","conditions":"Influenza, Healthy","enrollment":120},{"nctId":"NCT01146119","phase":"PHASE2","title":"Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2010-07","conditions":"Influenza","enrollment":200},{"nctId":"NCT01010737","phase":"PHASE1, PHASE2","title":"A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers","status":"COMPLETED","sponsor":"BiondVax Pharmaceuticals ltd.","startDate":"2009-09","conditions":"Influenza","enrollment":60},{"nctId":"NCT00467493","phase":"PHASE2","title":"Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers","status":"COMPLETED","sponsor":"Meditrina Pharmaceuticals","startDate":"2007-03","conditions":"Menstruation Disorders","enrollment":64}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Multimeric-001"],"phase":"phase_3","status":"active","brandName":"M-001","genericName":"M-001","companyName":"BiondVax Pharmaceuticals ltd.","companyId":"biondvax-pharmaceuticals-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"M-001 is a multivalent recombinant influenza vaccine designed to stimulate broad immune responses against multiple influenza strains. Used for Influenza prevention (universal/broad-spectrum protection).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}